The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000464369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
19/03/2026
Date registered
Help: Date registered
15/04/2026
Date last updated
Help: Date last updated
15/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Towards an Effective Treatment for Heart Complications After Surgery (feasibility study)
Scientific title
Secondary Prevention Therapy for Postoperative Myocardial Injury after Noncardiac Surgery (SPECTRE) feasibility trial
Additional trial identifiers [1] 316809 0
Nil known
Universal Trial Number (UTN)
Trial acronym
SPECTRE
Related trial records

Health condition
Health condition(s) studied:
Postoperative myocardial injury after non-cardiac surgery 341152 0
Condition category
Condition code
Surgery 337252 337252 0 0
Other surgery
Cardiovascular 337253 337253 0 0
Other cardiovascular diseases
Cardiovascular 337254 337254 0 0
Coronary heart disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The intervention group will receive secondary prevention therapy (for coronary artery disease) to treat postoperative myocardial injury (PMI).

This will comprise the following:
1. Inpatient Cardiologist review within 72 hours of diagnosis of PMI. This will involve assessment for cardiovascular risk factors, risk stratification (i.e. future risk of myocardial infarction, stroke). Other concurrent cardiac conditions (such as atrial fibrillation, heart failure) will also be assessed, and recommendations (for optimisation, ongoing treatment) will be provided, if indicated.

2. Cardiac rehabilitation (8 sessions) coordinated by Royal Melbourne Hospital Cardiac Rehabilitation Program

3. Risk factor modification (diabetes, hypertension, hyperlipidaemia). Blood pressure (BP) measurements during admission will be reviewed, for evidence of poorly controlled hypertension (systolic BP 130mmHg or greater, and/or diastolic BP 80mmHg or greater). HbA1c will be measured within 72 hours of diagnosis of PMI; values greater than 7% or 53mmol/mol will prompt more aggressive treatment of diabetes (or new diagnosis of diabetes). The Cardiology team will recommend treatments to optimise glycaemic control or, if required, obtain advice from the Endocrinology team regarding optimisation of diabetes. Lipid profile (including low-density lipoprotein [LDL] levels) will also be measured within 72 hours of diagnosis of PMI. LDL values 1.8mmol/L or greater will prompt treatment with a statin. If the participant is already on a statin, then ezetimibe or PCSK9 inhibitor will be prescribed, to achieve LDL < 1.8mmol/L. This risk factor modification will be initiated by the Cardiology team, and followed up by clinic visits with the research team at 3 months, 6 months and 12 months postoperatively.

4. Pharmacotherapy for secondary prevention of CAD
- All participants in the intervention arm will receive aspirin 100mg daily, atorvastatin 40mg daily. If the participant is already on a statin, with LDL 1.8mmol/L or greater at baseline, then ezetimibe 10mg daily will be added to the statin. Lipid profile will be re-checked at 3 months and 6 months postoperatively. If LDL targets are still not being met, despite statin therapy and ezetimibe, evolocumab 420mg (subcutaneous injection) monthly will be added.
- Bisoprolol 10mg daily and/or perindopril 10mg daily may be added, at the discretion of the Cardiologist. This will be on an individual basis. These medications will be up-titrated slowly, from 1.25mg daily as a starting dose.
- For those participants already on secondary prevention therapy, intensification of therapy will take place, at the discretion of the Cardiologist. This may include addition of a second antiplatelet agent (clopidogrel or ticagrelor), increase in dose of statin (to atorvastatin 80mg daily) or increase in dose of ACE-inhibitor or beta-blocker.
- Timing of anti-thrombotic therapy will also depend on the postoperative bleeding risk. The Cardiologist/research team will discuss with the surgical team (parent unit) the safest timing for initiation/intensification of antiplatelet therapy.

5. Lifestyle interventions will be implemented, where applicable, for all participants in the intervention group. These will be implemented, supervised and monitored by the research team. Lifestyle interventions will be reviewed at 3 months, 6 months and 1 year postoperatively. These will comprise the following:
Smoking cessation: Applicable if the participant has smoked any cigarettes within the past 6 months. Smoking advice as outlined in quit.org.au, education counselling and assistance with nicotine replacement therapy (if required).
Alcohol reduction: Applicable if the participant drinks 10 standard drinks or more per week, or 4 standard drinks or more on any day of the week. If indicated, appropriate education and advice regarding reducing alcohol intake, further counselling/assistance if required
Dietary modifications: Applicable if the participant's existing diet does not comprise of at least 80% Mediterranean diet. Education on the Mediterranean diet, with modifications to existing diet (as required) will be provided. Other considerations (such as cultural practices, food intolerances/allergies) will also influence dietary recommendations.
Physical activity: Applicable if the participant partakes in exercise that is less than 600 MET-minutes per week (as per the World Health Organisation Global Activity Questionnaire). Gradual increase in physical activity, towards World Health Organisation targets, will be prescribed. These will also incorporate Cardiac Rehabilitation exercises that have been prescribed. Furthermore, post-surgery considerations (such as weight-bearing, heavy lifting) will also be incorporated into physical activity recommendations.

TIME FRAME:
The intervention will commence within 7 days of surgery, and continue for 1 year postoperatively. This intervention refers to: i) pharmacotherapy; ii) risk factor modification and iii) lifestyle interventions, which will all run simultaneously and continuously for 1 year.
At the conclusion of the trial, a Cardiologist will assess the participant's cardiovascular risk and whether they are currently meeting guideline-recommended cardiovascular targets. Post-trial recommendations for secondary prevention therapy, ongoing surveillance and follow-up will then be individualised to the participant.

INITIATION OF INTERVENTION:
The intervention will be initiated in the surgical ward (during the index admission), and the participant will receive both verbal education (over 15-30 minutes) and written education from a member of the research team, regarding the three components of the intervention (pharmacotherapy, risk factor modification, lifestyle interventions).
Written information regarding the diagnosis of PMI, recommendations for pharmacotherapy, risk factor modification and lifestyle intervention will also be sent to the participant's primary care physician.


STRATEGIES TO MONITOR ADHERENCE:
Adherence to Refills and Medications (ARMS questionnaire)
Cardiac Rehabilitation Attendance questionnaire
Lifestyle interventions adherence questionnaire (smoking cessation, alcohol intake, physical activity, Mediterranean diet intake)
Cardiovascular targets review (systolic and diastolic blood pressure, HbA1c, lipid profile, body mass index, waist circumference measurements)

STRATEGIES TO MONITOR FIDELITY OF DELIVERY:
Fidelity of Delivery and Fidelity of Receipt records (for research team to complete), which records Cardiac Rehabilitation referral, provision of verbal and written education to the participant (intervention group), provision of written education to the primary care physician (intervention group), appropriate advice (as required) regarding physical activity, dietary intake, smoking cessation, alcohol reduction.
Intervention code [1] 333502 0
Treatment: Drugs
Intervention code [2] 333503 0
Prevention
Intervention code [3] 333504 0
Treatment: Other
Description of the comparator or control
The control group will receive standard care treatments for postoperative myocardial injury. This will comprise referral to the Cardiology team for participants who meet the criteria for review. These criteria are one or more of the following i) High-sensitivity troponin I elevation 5 times the upper reference limit (sex-specific); ii) Symptoms of myocardial ischaemia (chest pain, jaw/throat pain) and/or iii) New ischaemic ECG changes.

The following will take place at the discretion of the duty Cardiology team:
1. Cardiovascular risk assessment - predicting the individual's risk of future cardiovascular events (myocardial infarction, stroke), likelihood of occult coronary artery disease;
2. Further investigations (such as N-terminal pro-B type natriuretic peptide, echocardiogram, cardiac stress testing, coronary angiogram);
3. Secondary prevention therapy (one or more of: aspirin, statin, ACE-inhibitor, angiotensin receptor blocker) and
4. Outpatient Cardiologist follow-up.
Control group
Active

Outcomes
Primary outcome [1] 344774 0
Rate of recruitment
Timepoint [1] 344774 0
1 year after recruitment of first participant
Primary outcome [2] 344775 0
Rate of retention
Timepoint [2] 344775 0
2 years after recruitment of first participant
Primary outcome [3] 344776 0
Rate of participant adherence to interventions: Cardiac rehabilitation attendance.
Timepoint [3] 344776 0
1 year postoperatively
Secondary outcome [1] 459148 0
Clinical endpoint: 30-day myocardial infarction.
Timepoint [1] 459148 0
72 hours to 30 days postoperatively
Secondary outcome [2] 459149 0
Clinical endpoint: 1-year myocardial injury or myocardial infarction
Timepoint [2] 459149 0
31 days to 1 year postoperatively.
Secondary outcome [3] 459150 0
Clinical endpoint: 1-year percutaneous coronary intervention or coronary artery bypass grafting.
Timepoint [3] 459150 0
0 days to 1 year postoperatively.
Secondary outcome [4] 459759 0
Clinical endpoint: 1-year ischaemic stroke or transient ischaemic attack.
Timepoint [4] 459759 0
0 days to 1 year postoperatively.
Secondary outcome [5] 459760 0
1-year all-cause mortality.
Timepoint [5] 459760 0
0 days to 1 year postoperatively.
Secondary outcome [6] 459761 0
Safety endpoint: Bleeding following initiation or intensification of antithrombotic agents. Defined as intracranial, gastrointestinal or surgical site bleeding.
Timepoint [6] 459761 0
0 days to 1 year postoperatively.
Secondary outcome [7] 459762 0
Safety endpoint: Complications due to invasive coronary angiogram. Defined as myocardial infarction, stroke, coronary dissection, cardiac tamponade, death.
Timepoint [7] 459762 0
0 days to 1 year postoperatively.
Secondary outcome [8] 459763 0
Safety endpoint: Adverse events due to cardiac stress testing. Defined as chest pain, syncope, myocardial ischaemia, arrhythmia.
Timepoint [8] 459763 0
0 days to 1 year postoperatively.
Secondary outcome [9] 459764 0
Safety endpoint: Medication side-effects or adverse reactions, from beta-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), spironolactone or diabetes medications. Defined as postural hypotension or dizziness, falls, cough, angioedema, hypoglycaemia, euglycaemic ketoacidosis.
Timepoint [9] 459764 0
0 days to 1 year postoperatively.
Secondary outcome [10] 459765 0
Implementability endpoint: Acceptability of interventions.
Timepoint [10] 459765 0
6 months postoperatively
Secondary outcome [11] 459771 0
Implementability endpoint: Fidelity of delivery.
Timepoint [11] 459771 0
Checklists will be conducted at: 1. 8th session of Cardiac Rehabilitation 2. 12 months postoperatively
Secondary outcome [12] 459772 0
Implementability endpoint: Implementation feasibility (barriers and enablers to treatment adherence)
Timepoint [12] 459772 0
1. 4 weeks postoperatively 2. 6 months postoperatively
Secondary outcome [13] 460087 0
PRIMARY OUTCOME: Rate of participant adherence to smoking cessation (if applicable). If the participant is a non-smoker, then "not applicable" will be entered.
Timepoint [13] 460087 0
1 year postoperatively.
Secondary outcome [14] 460088 0
PRIMARY OUTCOME: Rate of alcohol intake reduction, to comply with guideline recommendations (maximum of 10 standard drinks per week, and no more than 4 standard drinks on any one night of the week).
Timepoint [14] 460088 0
1 year postoperatively.
Secondary outcome [15] 460089 0
PRIMARY OUTCOME: Rate of adherence to weekly physical activity recommendations.
Timepoint [15] 460089 0
1 year postoperatively
Secondary outcome [16] 460090 0
PRIMARY OUTCOME: Rate of adherence to a Mediterranean diet.
Timepoint [16] 460090 0
1 year postoperatively.
Secondary outcome [17] 460091 0
PRIMARY OUTCOME: Rate of adherence to pharmacotherapy.
Timepoint [17] 460091 0
1 year postoperatively.

Eligibility
Key inclusion criteria
1. Age 65 years and over;
2. Undergone non-cardiac surgery
3. Diagnosed with postoperative myocardial injury and
4. High-sensitivity cardiac troponin I (Abbott Architect assay) value of 60 ng/L or greater.
Minimum age
65 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Concurrent pulmonary embolism or sepsis;
2. Undergone palliative surgery;
3. Undergone cardiac surgery or interventional cardiology procedure;
4. Individuals who require an interpreter to understand the Participant Information and Consent Form (PICF) and/or medical instructions and
5. Unable to provide valid consent.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed opaque envelopes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29277 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment postcode(s) [1] 45588 0
3050 - Parkville

Funding & Sponsors
Funding source category [1] 321402 0
University
Name [1] 321402 0
University of Melbourne
Country [1] 321402 0
Australia
Funding source category [2] 321421 0
Charities/Societies/Foundations
Name [2] 321421 0
Australian and New Zealand College of Anaesthetists
Country [2] 321421 0
Australia
Funding source category [3] 321422 0
Hospital
Name [3] 321422 0
Royal Melbourne Hospital (City Campus - Parkville)
Country [3] 321422 0
Australia
Primary sponsor type
Hospital
Name
Melbourne Health
Address
Country
Australia
Secondary sponsor category [1] 324166 0
None
Name [1] 324166 0
Address [1] 324166 0
Country [1] 324166 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319943 0
Royal Melbourne Hospital Human Research Ethics Committee
Ethics committee address [1] 319943 0
Ethics committee country [1] 319943 0
Australia
Date submitted for ethics approval [1] 319943 0
26/11/2025
Approval date [1] 319943 0
30/01/2026
Ethics approval number [1] 319943 0
2025.194

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148902 0
Dr Earlene Silvapulle
Address 148902 0
Department of Anaesthesia and Pain Management. Royal Melbourne Hospital (City Campus). 300 Grattan Street, Parkville, VIC 3050.
Country 148902 0
Australia
Phone 148902 0
+61 393427540
Fax 148902 0
Email 148902 0
Contact person for public queries
Name 148903 0
Dr. Earlene Silvapulle
Address 148903 0
Department of Anaesthesia and Pain Management. Royal Melbourne Hospital (City Campus), 300 Grattan Street, Parkville VIC 3050.
Country 148903 0
Australia
Phone 148903 0
+61 393427000
Fax 148903 0
Email 148903 0
Contact person for scientific queries
Name 148904 0
Dr. Earlene Silvapulle
Address 148904 0
Department of Anaesthesia and Pain Management. Royal Melbourne Hospital (City Campus), 300 Grattan Street, Parkville VIC 3050.
Country 148904 0
Australia
Phone 148904 0
+61 393427540
Fax 148904 0
Email 148904 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.